--- title: "Lilly Reports Positive Topline Data From Phase III Obesity Study Of Retatrutide" type: "News" locale: "en" url: "https://longbridge.com/en/news/287212210.md" description: "Eli Lilly reported positive results from the Phase III TRIUMPH-1 trial for Retatrutide, showing significant weight loss in adults with obesity. At 80 weeks, participants lost an average of 64.4 pounds (25.9%) on the 9 mg dose and 70.3 pounds (28.3%) on the 12 mg dose. Additionally, 65.3% of those on the 12 mg dose achieved a BMI below 30. The drug also improved cardiovascular risk factors. Lilly shares closed at $1,018.87, down 0.25%." datetime: "2026-05-21T11:37:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287212210.md) - [en](https://longbridge.com/en/news/287212210.md) - [zh-HK](https://longbridge.com/zh-HK/news/287212210.md) --- # Lilly Reports Positive Topline Data From Phase III Obesity Study Of Retatrutide Add as your preferred news source on Google Add Now Eli Lilly and Company (LLY) on Thursday reported positive topline results from the Phase III TRIUMPH-1 trial evaluating Retatrutide in adults with obesity or overweight, at least one weight-related comorbidity, and without diabetes. At 80 weeks, all doses of retatrutide met the trial's primary and key secondary endpoints, delivering significant weight loss. Participants receiving the 9 mg and 12 mg doses lost an average of 64.4 pounds, or 25.9%, and 70.3 pounds, or 28.3%, respectively. Patients taking the 4 mg dose lost an average of 47.2 pounds, or 19.0%. Among participants taking the 12 mg dose, 65.3% achieved a body mass index below 30 at week 80, moving below the obesity threshold. This included 37.5% of patients who entered the trial with class 3 obesity, defined as a BMI of 40 or higher. In an extension study involving participants with a BMI of at least 35, those continuing treatment with retatrutide 12 mg through 104 weeks lost an average of 85 pounds, or 30.3%. The drug candidate also demonstrated improvements in several cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure and high-sensitivity C-reactive protein levels. Lilly shares closed at $1,018.87 on Wednesday, down 0.25%. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Eli Lilly Retatrutide 12 Mg Achieved 30.3% Average Weight Loss At 104 Weeks In Extension](https://longbridge.com/en/news/287203984.md) - [Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says](https://longbridge.com/en/news/287203888.md) - [Lilly's new experimental shot produced 28% weight loss](https://longbridge.com/en/news/287217267.md) - [Eli Lilly (LLY) Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?](https://longbridge.com/en/news/286629257.md) - [Trump purchased Eli Lilly stock as policies favored its drugs](https://longbridge.com/en/news/286791021.md)